Practitioner's Docket No. MPI93-006CP1DV1ACN1DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Sundelin, Johan, et al		
Application No.:	10/643,627	Group No.:	1636
Filed:	August 19, 2003	Examiner:	Guzo, David
For:	RECOMBINANT C140 RECEPTAND NUCLEIC ACIDS ENCODE		ONISTS AND ANTAGONISTS, EPTOR

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Sir:

网

Responsive to the Office action mailed April 6, 2005, please amend the above-identified application as follows and enter the remarks below:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 6 of this paper.

CHEDWINITA	TITORIY	DITIED OF	OPD O	COMMON O	/_Ÿ	3 1 10+
CERTIFICA) NULL	INDER 37	C.F.R. SI	ECTIONS 1.8	(a)	and Litur

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in for Patents, P.O. Box 1450, Alexandria, VA 2231		dressed to the Mail Stop Amendment, Commissioner
37 C.F.R. SECTION 1.8(a)	3 1 150.	37 C.F.R. SECTION 1.10*
with sufficient postage as first class mail.		as "Express Mail Post Office to Addressee"

as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION transmitted by facsimile to the Patent and Trademark Office.

Signature

Paula Swirka

Date: June 30, 2005 (type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 9)

RECEIVED **CENTRAL FAX CENTER**

JUN 3 0 2005

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In re application of:	Sundelin, Johan, et al.					
Application No.:	10/643,627	Group No.:	1636			
Filed:	August 19, 2003	Examiner:	Guzo, David			
For:	RECOMBINANT C140 RECEPTOR ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR					

Practitioner's Docket No. (MPI93-006CP1DV1ACN1DV1M)

PATENT

Certificate of Transmission under 37 CFR 1.8

1-703-872-9306

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

· on June 30, 2005

Signature

Paula Swirka

Typed or printed name of person signing Certificate

Submitted herewith:

This Certificate of Transmission under 37 CFR 1.8	1 page
Amendment and Response Transmittal (in duplicate)	2 pages
Amendment and Response	9 pages
Copy of IDS filed 8/19/2003	2 pages
with copies of Form PTO/SB/08A and Form PTO/SB/08B	2 pages
and copy of Reference B3	1 page
and copy of stamped return postcard receipt	1 page

Total Pages 18 pages

(including this cover sheet)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED CENTRAL FAX CENTER JUN 3 0 2005

Practitioner's Docket No. MPI93-006CP1DV1ACN1DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Sundelin, Johan, et al.		
Application No.:	10/643,627	Group No.:	1636
Filed:	August 19, 2003	Examiner:	Guzo, David
For:	RECOMBINANT C140 RECEPTAND NUCLEIC ACIDS ENCODI		CONISTS AND ANTAGONISTS,

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TRANSMITTAL

- 1. Transmitted herewith for this application are:
 - a. This Amendment and Response Transmittal (2 pages);
 - b. Amendment and Response (9 pages);
 - c. Copy of Information Disclosure Statement (IDS) filed 8/19/2003 (2 pages); with copies of Form PTO/SB/08A (1 page), Form PTO/SB/08B (1 page), reference B3 (1 page) and stamped return receipt postcard (1 page); and
 - d. Certificate of Transmission under 37 CFR 1.8 (1 page).

STATUS

2. Applicant is other than a small entity.

PETITION FOR EXTENSION OF TIME

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant believes an extension of time is not required. However, if an extension of time is required, please consider this a petition therefore:

Fee:

Extension fee due with this request \$0.00 CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10* I hereby certify that, on the date shown below, this correspondence is being: MAILING deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 37 C.F.R. SECTION 1.10* 37 C.F.R. SECTION 1.8(a) as "Express Mail Post Office to Addressee" with sufficient postage as first class mail. Mailing Label No. TRANSMISSION \boxtimes transmitted by facsimile to the Patent and Trademark Office (703-872-9306).

> Signature Paula Swirka

\$0.00

Date: June 30, 2005

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

RECEIVED CENTRAL FAX CENTER JUN 3 0 2005

Practitioner's Docket No. MPI93-006CP1DV1ACN1DV1M

If an additional extension of time is required, please consider this a petition therefor.

FEE FOR CLAIMS

The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	OTHER THAN A SMALL ENTITY			
	Claims Remaining Afte Amendment	er	Highest No. Previously Paid For		Present Extra	Rate		Addit. Fee
Total	17	Minus	20	=	0 ·	\$50.00	=	\$0.00
Indep.	3	Minus	3	=	0	\$200.00	=	\$0.00
First Presentation of Multiple Dependent Claims		0		,	\$360.00	=	\$0.00	
Ciainis						Total Addit. Fee		\$0.00
		To	otal additional fee	for cl	aims required	\$0.00		

FEE PAYMENT

5. Charge Account No. 501668 the sum of \$0.00 (which includes the \$0.00 additional fee for claims). A duplicate of this transmittal extension fee and the is attached.

FEE DEFICIENCY

- If any additional extension and/or fee is required, charge Account No. 501668. 6. If any additional fee for claims is required, charge Account No. 501668.
- 7. Correspondence Address Direct all future correspondence to:

Customer Number 30405

OR

Intellectual Property Department MILLENNIUM PHARMACEUTICALS, INC. 40 Landsdowne Street Cambridge, MA 02139

June 30, 2005

MILLENNIUM PHARMACEUTICALS, INC.

Tracy M. Sioussat, Ph.D.

Registration No. 50,609 40 Landsdowne Street Cambridge, MA 02139 Telephone - 617-374-7679 Facsimile - 617-551-8820